Herbal Spotlight
|
|
NEW WARNING
The Food and Drug Administration (FDA) is providing early communication about adverse events reported in patients taking deferasirox (Exjade). There may be a higher risk for kidney failure, GI hemorrhage, and death in patients with myelodysplastic syndrome (a condition in which the bone marrow doesn't function properly, causing anemia). Many of those affected have been older than age 60. However, advanced age, other medical disorders, and the need for blood transfusion in these patients have made it difficult for the FDA to make any conclusions.
Deferasirox has known adverse effects, some of which have been fatal. These effects included kidney and liver failure in patients who have other conditions that make them prone to kidney or liver problems or GI bleeding. Patients who have questions about their treatment should consult their health care provider.
The FDA is working with Novartis to revise prescribing information to warn health care professionals about the possible risks associated with deferasirox therapy. The FDA encourages health care professionals to report adverse effects using the FDA's MedWatch Adverse Event Reporting Program.
|
deferasirox